The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Atopic Dermatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.

Some of the key takeaways from the Atopic Dermatitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years. 
• Atopic Dermatitis companies working in the treatment market are Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, Kyowa Kirin, Kymab, LEO Pharma, Evelo Biosciences, Inc., GlaxoSmithKline, Biosion, Ribon Therapeutics, and others, are developing therapies for the Atopic Dermatitis treatment 

• Emerging Atopic Dermatitis therapies in the different phases of clinical trials are- PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, Rocatinlimab, Amlitelimab, LP 0145, Tozorakimab, EDP1815, GSK 1070806, BSI 045B, RBN-3143, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.   
• In November 2022, The first cohort of Alphyn Biologics’ Phase IIa clinical trial using AB-101a, a topical treatment option for mild-to-moderate atopic dermatitis (AD) in adults and children as young as two years old, has concluded, the company stated. Patients without bacterial infections, which are occasionally linked to AD, were included in the first cohort. We anticipate top-line findings in around eight weeks.
• In September 2022, In order to assess the safety and efficacy of si-544 in patients with mild to severe atopic dermatitis, as well as the length of therapeutic benefit, selectION stated that it has started treating patients in a Phase Ib trial.
• In July 2022, Connect Biopharma Holdings announced that it can now perform primary analysis of its ongoing pivotal trial for its lead product candidate, CBP-201, to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients. The announcement came from the Center for Drug Evaluation of the National Medical Products Administration (CDE). Connect Biopharma therefore intends to release the trial’s top-line results by year-end, ahead of schedule.
• In May 2022, In the single ascending dose Phase I clinical trial assessing BBI-02 in healthy adult subjects and patients with atopic dermatitis, Brickell Biotech reported that the first individuals had received their doses. BBI-02 is a novel, highly selective, oral bioavailable small molecule DYRK1A inhibitor that may be used to treat autoimmune and inflammatory patients. It works by regulating both innate and adaptive immune responses to promote immunological homeostasis.
• In January 2021, “A Phase III, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis” is the name of the Phase III experiment that Arcutis Biotherapeutics started.

Atopic Dermatitis Overview

The most prevalent kind of skin inflammation, atopic dermatitis (AD), often known as eczema, is a chronic disorder that typically begins in early childhood but can occur at any age and can be recurrent or persistent throughout life. When we say “dermatitis,” Derm refers to skin, and itis denotes inflammation.

Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight

Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:

• PF 07242813: Pfizer
• KT-474: Kymera Therapeutics
• BEN2293: BenevolentAI
• MEDI3506: AstraZeneca
• Q301: Qurient
• SB011: Sterna Biologicals
• Tradipitant: Vanda Pharmaceuticals
• Roflumilast: Arcutis Biotherapeutics
• Rocatinlimab: Kyowa Kirin
• Amlitelimab: Kymab
• LP 0145: LEO Pharma
• Tozorakimab: AstraZeneca
• EDP1815: Evelo Biosciences, Inc.
• GSK 1070806: GlaxoSmithKline
• BSI 045B: Biosion
• RBN-3143: Ribon Therapeutics

Atopic Dermatitis Route of Administration

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Atopic Dermatitis Molecule Type

Atopic Dermatitis Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Atopic Dermatitis Pipeline Therapeutics Assessment

• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage and Product Type
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis By Stage and Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
• Atopic Dermatitis by Stage and Molecule Type

DelveInsight’s Atopic Dermatitis Report covers around 110+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies

Some of the key companies in the Atopic Dermatitis Therapeutics Market include:

Key companies developing therapies for Atopic Dermatitis are – Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, and others.

Atopic Dermatitis Pipeline Analysis:

The Atopic Dermatitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
• Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies

Atopic Dermatitis Pipeline Market Drivers

• Rising prevalence of AD, escalating expenditure on health care, potential Emerging Therapies are some of the important factors that are fueling the Atopic Dermatitis Market.

Atopic Dermatitis Pipeline Market Barriers

• However, over-the-counter medications, outdated treatment recommendations, poor prognosis and treatment adherence and other factors are creating obstacles in the Atopic Dermatitis Market growth.

Scope of Atopic Dermatitis Pipeline Drug Insight    

• Coverage: Global
• Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, Kyowa Kirin, Kymab, LEO Pharma, Evelo Biosciences, Inc., GlaxoSmithKline, Biosion, Ribon Therapeutics, and others
• Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, Rocatinlimab, Amlitelimab, LP 0145, Tozorakimab, EDP1815, GSK 1070806, BSI 045B, RBN-3143, and others
• Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers 

Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials

Table of Contents

1. Atopic Dermatitis Report Introduction

2. Atopic Dermatitis Executive Summary

3. Atopic Dermatitis Overview

4. Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment

5. Atopic Dermatitis Pipeline Therapeutics

6. Atopic Dermatitis Late Stage Products (Phase II/III)

7. Atopic Dermatitis Mid Stage Products (Phase II)

8. Atopic Dermatitis Early Stage Products (Phase I)

9. Atopic Dermatitis Preclinical Stage Products

10. Atopic Dermatitis Therapeutics Assessment

11. Atopic Dermatitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Atopic Dermatitis Key Companies

14. Atopic Dermatitis Key Products

15. Atopic Dermatitis Unmet Needs

16 . Atopic Dermatitis Market Drivers and Barriers

17. Atopic Dermatitis Future Perspectives and Conclusion

18. Atopic Dermatitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services